SGLT抑制剂用于1型糖尿病心肾疾病治疗的路径探讨
本文由内分泌、肾脏与心脏领域专家联合阐述SGLT抑制剂在1型糖尿病(T1D)心肾疾病中的疗效与安全性数据,并探讨2型糖尿病(T2D)及非糖尿病人群数据向T1D的外推。专家认为相关机制可能同样适用于T1D,注册试验或可采用替代终点,同时须严格收集与防范糖尿病酮症酸中毒(DKA)。
要点
- SGLT抑制剂在T2D及非糖尿病人群中的心肾保护机制可能同样适用于T1D。
- T1D注册试验或可基于合适的替代终点设计,而不必以传统事件终点作为主要把握度依据。
- DKA是T1D使用SGLT抑制剂的关键风险,须严格实施风险防范方案并收集相关数据。
核心结论
- SGLT抑制剂在T2D和非糖尿病人群中驱动心肾疗效的机制很可能适用于T1D。
- 鉴于T2D与非糖尿病人群的疗效数据,T1D注册试验可能无需以传统事件为基础的主要终点进行把握度设计,而可依赖合适的替代终点。
- DKA风险防范是T1D使用SGLT抑制剂的关键,但现有防范方案缺乏严格的有效性数据。
研究设计与样本
- 本文为专家视角文章,作者来自内分泌学、肾脏病学和心脏病学领域。
- 文章汇总SGLT抑制剂在T1D中的疗效与安全性现有数据,并讨论T2D及非糖尿病人群数据向T1D的外推。
主要发现
- T2D和非糖尿病心肾疾病中SGLT抑制剂的疗效机制可能适用于T1D。
- 基于替代终点的可行试验设计可支持T1D注册试验的推进。
- T1D使用SGLT抑制剂时须仔细收集与DKA相关的数据。
关键数值与推荐
- T1D注册试验可考虑采用合适的替代终点,而非传统事件为基础的主要终点。
- T1D使用SGLT抑制剂须实施DKA风险防范方案并严格收集DKA相关数据。
临床怎么用
- 在内分泌、肾脏与心脏多学科协作下评估T1D患者使用SGLT抑制剂的心肾获益与DKA风险。
- 使用SGLT抑制剂时执行DKA风险防范方案并系统收集DKA相关数据。
局限性
- DKA风险防范方案虽已制定,但缺乏严格的有效性数据。
- T1D中SGLT抑制剂的心肾结局证据仍需注册试验验证,尚待监管批准。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Developing a path forward for sodium-glucose cotransporter (SGLT) inhibitor treatment for heart and kidney disease in people with type 1 diabetes (T1D) is essential. This article offers the perspective of experts from the fields of endocrinology, nephrology, and cardiology on available data for the efficacy and safety of SGLT inhibitors in T1D, how the far more extensive data from people with type 2 diabetes (T2D) and people without diabetes would be expected to translate to T1D, and what steps are required to advance toward regulatory approvals and clinical uptake of SGLT inhibitors in T1D for heart and kidney disease. Our conclusion is that the mechanisms driving efficacy of SGLT inhibitors for heart and kidney disease in T2D and nondiabetic disease are likely applicable to T1D and that in light of the data supporting efficacy in these populations, registrational trials in T1D might not require powering for traditional event-based outcomes and investigators may instead rely on suitable surrogate end points, allowing for more feasible trials. Investigators in these trials must also carefully collect data associated with diabetic ketoacidosis (DKA), the critical risk of SGLT inhibitor use in T1D. DKA risk mitigation is essential for SGLT inhibitor use in T1D; protocols to mitigate risk have been developed, but rigorous data on their effectiveness are lacking. We describe a roadmap to advance SGLT inhibitors for T1D heart and kidney disease, which includes the use of feasible trial designs based on surrogate end points and rigorous safety protocols to minimize DKA events.
引用
- Rosen J, de Boer IH, Eckel RH, et al. SGLT Inhibitors for Heart and Kidney Disease in Type 1 Diabetes. Diabetes Care. 2026. PMID: 42690158. doi:10.2337/dc26-0999
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。